{"schema_version":"secwatch.filing_event.v1","accession":"0001356576-22-000071","form_type":"8-K","ticker":"SUPN","cik":"0001356576","company_name":"SUPERNUS PHARMACEUTICALS, INC.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.310853+00:00","generated_at":"2026-06-22T03:09:11.059224+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Supernus Q3 revenue $177.4M (+19% YoY); guides FY2022 revenue $650-680M","bullets":["GAAP net earnings $1.7M ($0.03 diluted EPS); adjusted op earnings $25.4M vs $43.3M prior year.","Total revenues $177.4M (+19% YoY); Qelbree sales $18.3M (+65% QoQ) with 94,328 prescriptions.","FY 2022 guidance raised: total revenue $650-680M (from $640-680M) and GAAP op earnings $35-45M (from $20-40M).","FDA issued CRL for SPN-830 (apomorphine device; Parkinson's); no new efficacy/safety trials needed but device and quality info required; Class 2 review timeline (6 months)."],"urls":{"canonical":"https://secwatch.observer/filing/0001356576-22-000071","json":"https://secwatch.observer/filing/0001356576-22-000071.json","markdown":"https://secwatch.observer/filing/0001356576-22-000071.md","text":"https://secwatch.observer/filing/0001356576-22-000071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1356576/000135657622000071/0001356576-22-000071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1356576/000135657622000071/supn-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:09:11.059224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f1396eff43ebfa1a8295b4143cd64fabe0577e1b","claim":"SUPERNUS PHARMACEUTICALS, INC. updated its third quarter ended September 30, 2022 guidance (raised).","evidence_excerpt":"Supernus Announces Third Quarter 2022 Financial Results • Third quarter 2022 total revenues of $177.4 million, a 19% increase compared to third quarter 2021 • Increasing full year 2022 operating earnings guidance to $35 million to $45 million, from $20 million to $40 million previously • Increasing full year 2022 total revenues guidance to $650 million to $680 million, from $640 million to $680 million previously","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1356576/000135657622000071/0001356576-22-000071-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}